Diabetic Macular Edema and Diode Subthreshold Micropulse Laser : A Randomized Double-Masked Noninferiority Clinical Trial
Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved..
PURPOSE: To determine clinical effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 μm.
DESIGN: Pragmatic, multicenter, allocation-concealed, double-masked, randomized, noninferiority trial.
PARTICIPANTS: Adults with center-involved DME < 400 μm and best-corrected visual acuity (BCVA) of > 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in one/both eyes.
METHODS: Randomization 1:1 to 577 nm SML or SL treatment. Retreatments were allowed. Rescue with intravitreal anti-vascular endothelial growth factor therapies or steroids was permitted if 10 or more ETDRS letter loss occurred, CRT increased > 400 μm, or both.
MAIN OUTCOME MEASURES: Primary outcome was mean change in BCVA in the study eye at 24 months (noninferiority margin 5 ETDRS letters). Secondary outcomes were mean change from baseline to month 24 in binocular BCVA; CRT and mean deviation of Humphrey 10-2 visual field in the study eye; percentage meeting driving standards; EuroQoL EQ-5D-5L, 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), and Vision and Quality of Life Index (VisQoL) scores; cost per quality-adjusted life-years (QALYs) gained; adverse effects; and number of laser and rescue treatments.
RESULTS: The study recruited fully (n = 266); 87% of SML-treated and 86% of SL-treated patients had primary outcome data. Mean ± standard deviation BCVA change from baseline to month 24 was -2.43 ± 8.20 letters and -0.45 ± 6.72 letters in the SML and SL groups, respectively. Subthreshold micropulse laser therapy was deemed not only noninferior but also equivalent to SL therapy because the 95% confidence interval (CI; -3.9 to -0.04 letters) lay wholly within both upper and lower margins of the permitted maximum difference (5 ETDRS letters). No statistically significant difference was found in binocular BCVA (0.32 ETDRS letters; 95% CI, -0.99 to 1.64 ETDRS letters; P = 0.63); CRT (-0.64 μm; 95% CI, -14.25 to 12.98 μm; P = 0.93); mean deviation of the visual field (0.39 decibels (dB); 95% CI, -0.23 to 1.02 dB; P = 0.21); meeting driving standards (percentage point difference, 1.6%; 95% CI, -25.3% to 28.5%; P = 0.91); adverse effects (risk ratio, 0.28; 95% CI, 0.06-1.34; P = 0.11); rescue treatments (percentage point difference, -2.8%; 95% CI, -13.1% to 7.5%; P = 0.59); or EQ-5D, NEI-VFQ-25, or VisQoL scores. Number of laser treatments was higher in the SML group (0.48; 95% CI, 0.18-0.79; P = 0.002). Base-case analysis indicated no differences in costs or QALYs.
CONCLUSIONS: Subthreshold micropulse laser therapy was equivalent to SL therapy, requiring slightly higher laser treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Ophthalmology - 130(2023), 1 vom: 05. Jan., Seite 14-27 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lois, Noemi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.12.2022 Date Revised 04.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ophtha.2022.08.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344922537 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344922537 | ||
| 003 | DE-627 | ||
| 005 | 20231226023902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ophtha.2022.08.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344922537 | ||
| 035 | |a (NLM)35973593 | ||
| 035 | |a (PII)S0161-6420(22)00631-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lois, Noemi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetic Macular Edema and Diode Subthreshold Micropulse Laser |b A Randomized Double-Masked Noninferiority Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2022 | ||
| 500 | |a Date Revised 04.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To determine clinical effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 μm | ||
| 520 | |a DESIGN: Pragmatic, multicenter, allocation-concealed, double-masked, randomized, noninferiority trial | ||
| 520 | |a PARTICIPANTS: Adults with center-involved DME < 400 μm and best-corrected visual acuity (BCVA) of > 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in one/both eyes | ||
| 520 | |a METHODS: Randomization 1:1 to 577 nm SML or SL treatment. Retreatments were allowed. Rescue with intravitreal anti-vascular endothelial growth factor therapies or steroids was permitted if 10 or more ETDRS letter loss occurred, CRT increased > 400 μm, or both | ||
| 520 | |a MAIN OUTCOME MEASURES: Primary outcome was mean change in BCVA in the study eye at 24 months (noninferiority margin 5 ETDRS letters). Secondary outcomes were mean change from baseline to month 24 in binocular BCVA; CRT and mean deviation of Humphrey 10-2 visual field in the study eye; percentage meeting driving standards; EuroQoL EQ-5D-5L, 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), and Vision and Quality of Life Index (VisQoL) scores; cost per quality-adjusted life-years (QALYs) gained; adverse effects; and number of laser and rescue treatments | ||
| 520 | |a RESULTS: The study recruited fully (n = 266); 87% of SML-treated and 86% of SL-treated patients had primary outcome data. Mean ± standard deviation BCVA change from baseline to month 24 was -2.43 ± 8.20 letters and -0.45 ± 6.72 letters in the SML and SL groups, respectively. Subthreshold micropulse laser therapy was deemed not only noninferior but also equivalent to SL therapy because the 95% confidence interval (CI; -3.9 to -0.04 letters) lay wholly within both upper and lower margins of the permitted maximum difference (5 ETDRS letters). No statistically significant difference was found in binocular BCVA (0.32 ETDRS letters; 95% CI, -0.99 to 1.64 ETDRS letters; P = 0.63); CRT (-0.64 μm; 95% CI, -14.25 to 12.98 μm; P = 0.93); mean deviation of the visual field (0.39 decibels (dB); 95% CI, -0.23 to 1.02 dB; P = 0.21); meeting driving standards (percentage point difference, 1.6%; 95% CI, -25.3% to 28.5%; P = 0.91); adverse effects (risk ratio, 0.28; 95% CI, 0.06-1.34; P = 0.11); rescue treatments (percentage point difference, -2.8%; 95% CI, -13.1% to 7.5%; P = 0.59); or EQ-5D, NEI-VFQ-25, or VisQoL scores. Number of laser treatments was higher in the SML group (0.48; 95% CI, 0.18-0.79; P = 0.002). Base-case analysis indicated no differences in costs or QALYs | ||
| 520 | |a CONCLUSIONS: Subthreshold micropulse laser therapy was equivalent to SL therapy, requiring slightly higher laser treatments | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anti-VEGF | |
| 650 | 4 | |a DME | |
| 650 | 4 | |a Diabetic macular edema | |
| 650 | 4 | |a Macular laser | |
| 650 | 4 | |a Micropulse | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Ranibizumab |2 NLM | |
| 650 | 7 | |a ZL1R02VT79 |2 NLM | |
| 700 | 1 | |a Campbell, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Waugh, Norman |e verfasserin |4 aut | |
| 700 | 1 | |a Azuara-Blanco, Augusto |e verfasserin |4 aut | |
| 700 | 1 | |a Maredza, Mandy |e verfasserin |4 aut | |
| 700 | 1 | |a Mistry, Hema |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Acharya, Nachiketa |e verfasserin |4 aut | |
| 700 | 1 | |a Aslam, Tariq M |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Downey, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Eleftheriadis, Haralabos |e verfasserin |4 aut | |
| 700 | 1 | |a Fatum, Samia |e verfasserin |4 aut | |
| 700 | 1 | |a George, Sheena |e verfasserin |4 aut | |
| 700 | 1 | |a Ghanchi, Faruque |e verfasserin |4 aut | |
| 700 | 1 | |a Groppe, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Geeta |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Sivaprasad, Sobha |e verfasserin |4 aut | |
| 700 | 1 | |a Shiew, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Steel, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Talks, James Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Doherty, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a McDowell, Cliona |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Mike |e verfasserin |4 aut | |
| 700 | 0 | |a DIAMONDS Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmology |d 1993 |g 130(2023), 1 vom: 05. Jan., Seite 14-27 |w (DE-627)NLM000457019 |x 1549-4713 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2023 |g number:1 |g day:05 |g month:01 |g pages:14-27 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ophtha.2022.08.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2023 |e 1 |b 05 |c 01 |h 14-27 | ||